Cagrilintide
NeuroprotectionNeurology research on Cagrilintide examines whether this long-acting amylin analogue produces measurable CNS effects beyond peripheral activity. The cognitive case rests on three convergent threads: selectively activates the amylin receptor (calcitonin receptor + ramp1/3 complex) slows gastric emptying, suppresses postprandial glucagon, and acts centrally in the area postrema to suppress appetite. the c16 fatty-acid sidechain enables albumin binding and once-weekly dosing.; downstream consequences for monoamine and neurotrophic signalling; and reduction of chronic neuroinflammation. Cagrilintide is dosed at 1.2-2.4 mg 1x weekly subq via subq in cognitive-focused protocols, with the ~7 days pharmacokinetic profile shaping receptor occupancy timing.
Key Takeaways
Cognitive lens: Cagrilintide acts as a restorative compound rather than a stimulant for cognitive endpoints. CNS access pattern: BBB transport plus vagal-afferent gut-brain signalling and cerebral vascular effects. Mechanism: Selectively activates the amylin receptor (calcitonin receptor + RAMP1/3 complex). Neuro dose: 1.2-2.4 mg 1x weekly subq via subq; cognitive effects accumulate across 4-8 weeks. Cognitive stack partners: Semax, Selank, Semax + Selank Blend.
Selectively activates the amylin receptor (calcitonin receptor + RAMP1/3 complex). Slows gastric emptying, suppresses postprandial glucagon, and acts centrally in the area postrema to suppress appetite. The C16 fatty-acid sidechain enables albumin binding and once-weekly dosing. For cognitive endpoints specifically, this mechanism translates into restorative rather than stimulant effects: reduction of neuroinflammation, support for BDNF and NGF signalling, modulation of monoamine systems, and stabilisation of cerebral perfusion. The three subsections below examine Cagrilintide's CNS access route, the neurotrophic and inflammatory effects, and the receptor-level pharmacology.
Monoamine and neurotrophic effects
Cagrilintide's downstream effects on monoamine systems (dopamine, serotonin, occasionally noradrenaline) and on neurotrophic signalling (BDNF, NGF, NT-3) form the molecular substrate of its observed cognitive phenotype. Selectively activates the amylin receptor (calcitonin receptor + RAMP1/3 complex). Slows gastric emptying, suppresses postprandial glucagon, and acts centrally in the area postrema to suppress appetite. The C16 fatty-acid sidechain enables albumin binding and once-weekly dosing. For users tracking cognitive endpoints over the typical 1x weekly subq dosing pattern at 1.2-2.4 mg, the changes accumulate across 4–8 weeks rather than emerging acutely. The relevant clinical endpoints are sleep quality, recovery capacity, mood stability, and resilience to cognitive stressors.
Receptor pharmacology and selectivity profile
Cagrilintide's receptor-level pharmacology determines its selectivity profile and its overlap with companion peptides. Selectively activates the amylin receptor (calcitonin receptor + RAMP1/3 complex). Slows gastric emptying, suppresses postprandial glucagon, and acts centrally in the area postrema to suppress appetite. The C16 fatty-acid sidechain enables albumin binding and once-weekly dosing. The selectivity (or lack thereof) for the principal target relative to off-target receptors is the basis for both the clinical phenotype and the side-effect profile. In stack design this matters: pairing Cagrilintide with peptides engaging the same primary receptor produces competition rather than synergy.
Central nervous system access
Cagrilintide reaches the central nervous system through one or more of three documented routes: direct blood-brain barrier transport, vagal-afferent signalling via the gut-brain axis, and direct action on cerebral vasculature in regions where the barrier is locally compromised. The compound's subq route(s) and ~7 days half-life set the timeline for CNS exposure. Selectively activates the amylin receptor (calcitonin receptor + RAMP1/3 complex). The CNS-relevant phenotype that emerges from this mechanism is the substrate of the cognitive effects described below.
Where Cagrilintide is used for chronic neuroinflammation, the dosing window is typically 4–8 weeks with re-evaluation at the end of cycle. Stacking with selank or semax is common in this use case; pure-isolated dosing is also viable for first-cycle users.
For bdnf support, Cagrilintide is most-relevant in users whose cognitive complaints track with chronic neuroinflammation or post-injury recovery. Effect size is modest but consistent across well-tolerated dose ranges, with typical response window of 4–8 weeks.
Focus & Executive Function is one of the more-reported subjective benefits of Cagrilintide across cognitive-focused user cohorts. The mechanism is plausible given the compound's neurotrophic and anti-inflammatory profile; the effect size depends substantially on baseline status.
Where Cagrilintide is used for stroke recovery, the dosing window is typically 4–8 weeks with re-evaluation at the end of cycle. Stacking with selank or semax is common in this use case; pure-isolated dosing is also viable for first-cycle users.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 1.2-2.4 mg | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 1.2-2.4 mg | 4–6 weeks initial cycle |
| Neuroprotection focus | SubQ | 1.2-2.4 mg | 1x weekly SubQ |
| Maintenance phase | SubQ | 1.2-2.4 mg | Ongoing with periodic pauses |
Dose timing for Cagrilintide is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses.
Cagrilintide stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from the cognitive neuroscience community.
- Cagrilintide + Semax: Elevates BDNF and NGF in hippocampus and cortex. Pairs naturally with Cagrilintide's mechanism in cognitive / neurological protocols.
- Cagrilintide + Selank: Modulates GABA-A receptor systems indirectly. Pairs naturally with Cagrilintide's mechanism in cognitive / neurological protocols.
- Cagrilintide + Semax + Selank Blend: Semax raises BDNF and modulates dopamine systems; Selank stabilises GABAergic and serotonergic tone. Pairs naturally with Cagrilintide's mechanism in cognitive / neurological protocols.
- Cagrilintide + DSIP: Mechanism remains incompletely characterised. Pairs naturally with Cagrilintide's mechanism in cognitive / neurological protocols.
Gastrointestinal events most common (nausea, vomiting), generally lower than GLP-1 mono-therapy. Pancreatitis caution; avoid in pregnancy.
Lens-specific safety considerations for cognitive / neurological use of Cagrilintide: Gastrointestinal events most common (nausea, vomiting), generally lower than GLP-1 mono-therapy. Pancreatitis caution; avoid in pregnancy. Additional cognitive / neurological monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| Cagrilintide | Long-acting amylin analogue | ~7 days | Neuroprotection |
| Semax | ACTH-derived nootropic heptapeptide | CNS effect hours; plasma minutes | A Russian-developed analogue of ACTH(4-10) extended with a Pro-Gly-Pro tail for proteolytic stability — a clinically used nootropic and stroke recovery agent |
| Selank | Tuftsin-derived heptapeptide anxiolytic | CNS effect lasts hours; plasma short | A Russian-developed heptapeptide derived from tuftsin — anxiolytic without sedation, supported by clinical trial data in generalised anxiety disorder |
| DSIP | Neuropeptide (sleep) | ~7 min plasma; CNS effects longer | A short neuropeptide isolated from sleeping rabbits in 1977, of interest for its modulation of delta-wave sleep and stress resilience |
| Pinealon | Khavinson tripeptide (pineal-derived) | Short plasma; durable tissue effects | A Khavinson pineal-derived tripeptide of glutamate-aspartate-arginine, studied for neuroprotection and cognitive function in aged and ischemic models |
How long until I notice cognitive effects?
Cognitive side effects to watch for?
Best route for cognitive applications — injection or oral?
Can Cagrilintide be stacked with other nootropics?
What is the mechanism of action of Cagrilintide?
How long until I see results from Cagrilintide?
Start a Cagrilintide Protocol
Alukard provides physician-supervised cognitive protocols with GMP-certified Cagrilintide and GMP-certified compounds and comprehensive neurological assessments.
Get ProtocolQuick Facts
- Molecular weight
- ~4400 Da
- Sequence length
- 37 aa
- Half-life
- ~7 days
- WADA
- Not on prohibited list
- FDA
- Investigational (Phase III combined with semaglutide as CagriSema)
- Research
- Phase III trials underway
Stack Partners
All cognitive / neurological applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Cagrilintide unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Cognitive / Neurological Protocol for Cagrilintide
Alukard provides physician-supervised cognitive protocols with GMP-certified compounds and comprehensive neurological assessments.
HIPAA Compliant · GMP Certified · Physician Supervised